Francesco Dituri

Summary

Country: Italy

Publications

  1. ncbi PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors
    Francesco Dituri
    Department of Emergency and Organ Transplantation, Section of Internal Medicine, Allergology and Clinical Immunology, University of Bari Medical School, 70124 Bari, Italy
    Clin Dev Immunol 2011:947858. 2011
  2. ncbi Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts
    Antonio Mazzocca
    Department of Internal Medicine, Immunology, and Infectious Diseases, Section of Internal Medicine, University of Bari Medical School, Bari, Italy
    Hepatology 54:920-30. 2011
  3. ncbi PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma
    Francesco Dituri
    Department of Internal Medicine, Immunology and Infectious Diseases, Section of Internal Medicine, University of Bari Medical School, Bari, Italy
    Int J Cancer 130:2505-13. 2012
  4. ncbi Hepatic stellate cells stimulate HCC cell migration via laminin-5 production
    Angela Santamato
    Department of Internal Medicine, Immunology and Infectious Diseases, Section of Internal Medicine, University of Bari Medical School, Bari, Italy
    Clin Sci (Lond) 121:159-68. 2011
  5. ncbi Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma
    Antonio Mazzocca
    Department of Internal Medicine, Section of Internal Medicine, Policlinico, Bari, Italy
    Hepatology 51:523-34. 2010

Collaborators

Detail Information

Publications5

  1. ncbi PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors
    Francesco Dituri
    Department of Emergency and Organ Transplantation, Section of Internal Medicine, Allergology and Clinical Immunology, University of Bari Medical School, 70124 Bari, Italy
    Clin Dev Immunol 2011:947858. 2011
    ..In addition, we discuss, from antitumor immunological point of view, the potential benefits and disadvantages arising from use of anticancer pharmacological agents targeting the PI3K pathway...
  2. ncbi Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts
    Antonio Mazzocca
    Department of Internal Medicine, Immunology, and Infectious Diseases, Section of Internal Medicine, University of Bari Medical School, Bari, Italy
    Hepatology 54:920-30. 2011
    ..Inhibition of LPA could prove effective in blocking transdifferentiation of myofibroblasts and tumor progression...
  3. ncbi PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma
    Francesco Dituri
    Department of Internal Medicine, Immunology and Infectious Diseases, Section of Internal Medicine, University of Bari Medical School, Bari, Italy
    Int J Cancer 130:2505-13. 2012
    ..Our results emphasize the role of p110γ as a promoter of HCC proliferation and unveil an important cell cycle regulation function of this molecule...
  4. ncbi Hepatic stellate cells stimulate HCC cell migration via laminin-5 production
    Angela Santamato
    Department of Internal Medicine, Immunology and Infectious Diseases, Section of Internal Medicine, University of Bari Medical School, Bari, Italy
    Clin Sci (Lond) 121:159-68. 2011
    ..In human HCC tissues, Ln-5 is mainly distributed along α-SMA (smooth muscle actin)-positive cells, whereas in peritumoural tissues, Ln-5 is absent. HSCs stimulate HCC migration via the production and secretion of Ln-5...
  5. ncbi Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma
    Antonio Mazzocca
    Department of Internal Medicine, Section of Internal Medicine, Policlinico, Bari, Italy
    Hepatology 51:523-34. 2010
    ..CONCLUSION: Taken together, our preclinical results indicate that LY2109761 targets the cross-talk between HCC and the stroma and provide a rationale for future clinical trials...